Alzheimer’s Blood Tests Are Going Mainstream, and Scientists Are Nervous
A blood test that can detect Alzheimer’s disease years before symptoms appear sounds like unambiguous progress. But as these tests expand beyond specialist clinics into routine healthcare, researchers are raising uncomfortable questions about what we do with the results.
Alzheimer’s begins at the molecular level decades before anyone notices memory problems. Protein clusters, amyloid-beta and tau, accumulate in the brain long before cognitive decline becomes apparent. Blood tests capable of detecting these proteins have improved dramatically in recent years. They are cheaper than brain imaging, less invasive than spinal taps, and increasingly accurate. Now they are being deployed, or are about to be, at a scale that goes far beyond the specialized memory clinics where they were developed.
A Science article presents a critical assessment from researchers who are not opposed to the tests themselves, but are concerned about what happens when they reach a general population. What do you tell a 55-year-old with no symptoms that their blood markers suggest elevated risk of Alzheimer’s in 15 years? What does that knowledge do to them, psychologically, in terms of insurance, in terms of how they plan their lives?
What the test actually measures, and what it doesn’t
The blood tests primarily measure the ratio of amyloid fragments, or the concentration of phospho-tau, a chemically modified form of the tau protein that is characteristic of Alzheimer’s pathology. High values correlate strongly with the presence of Alzheimer’s changes in the brain. But correlation is not the same as certainty. Some people with elevated markers never develop clinical Alzheimer’s. Others with relatively normal values do.
There is also limited evidence that early detection leads to better patient outcomes, particularly given that therapeutic options remain narrow. The newer antibody therapies such as lecanemab and donanemab can slow disease progression in some patients, but they are not cures, and they carry significant side effects. If you know you are accumulating amyloid but have no symptoms yet, the menu of actionable responses is thinner than the optimism around these tests might suggest.
The gap between possible and advisable
The broader issue the Science article raises is a familiar tension in medicine: the difference between what is technically feasible and what is medically wise. Screening programs have a well-documented history of overdiagnosis, identifying abnormalities that would never have caused problems, and the psychological and medical harm that follows is real and measurable.
For longevity researchers, Alzheimer’s is one of the most urgent targets precisely because it is one of the primary drivers of lost healthy years in old age. But the blood test debate illustrates that better diagnostics and better care are not the same thing. What to do with knowledge that cannot yet be reliably translated into action remains, for now, an open question.